35 results on '"Lucy Y. Liu"'
Search Results
2. Duality and Ambiguity in Britten’s Death in Venice
- Author
-
Lucy Y. Liu
- Subjects
Music ,M1-5000 - Published
- 2011
- Full Text
- View/download PDF
Catalog
3. Brahms's ‘Musical Prose’ Reconsidered
- Author
-
LUCY Y. LIU
- Subjects
Music - Published
- 2022
- Full Text
- View/download PDF
4. Mimickers of Classical Urticaria: Cryopyrin-Associated Autoinflammatory Syndrome Presenting as Isolated Urticaria in an Infant
- Author
-
Benjamin D. Solomon, Meliha Skaljic, Lucy Y. Liu, Di Yan, Kathleen M. Sheahon, Lori Broderick, Hal M. Hoffman, Shannon J. Beres, Ryanne A. Brown, Joyce M.C. Teng, and Yael Gernez
- Subjects
Immunology and Allergy - Published
- 2023
- Full Text
- View/download PDF
5. Eyebrows Are Important in the Treatment of Alopecia Areata
- Author
-
Lucy Y. Liu, Justin M. Ko, and Brett A. King
- Subjects
Adult ,Male ,medicine.medical_specialty ,Alopecia Areata ,Dermatology ,Treatment goals ,Patient Care Planning ,Hair growth ,Surveys and Questionnaires ,Photography ,otorhinolaryngologic diseases ,medicine ,Humans ,skin and connective tissue diseases ,Molecular Biology ,Scalp ,integumentary system ,business.industry ,Extramural ,Outcome measures ,Cell Biology ,General Medicine ,Middle Aged ,Alopecia areata ,medicine.disease ,Response to treatment ,Body hair ,body regions ,medicine.anatomical_structure ,Patient Satisfaction ,Female ,sense organs ,Eyebrows ,business ,Hair ,Biotechnology - Abstract
Alopecia areata affects not only scalp hair but also other sites of body hair, including eyebrows. Our objective was to investigate the importance of eyebrows in the treatment goals of patients with alopecia areata. Through an online questionnaire, subjects were asked to assess satisfaction with the visually depicted level of response to treatment, using edited photographs depicting a range of eyebrows and scalp hair growth. The questionnaire was completed by 1,741 adults. Absent or partial growth of eyebrows and scalp hair elicited25% satisfaction. Images depicting either complete eyebrows or complete scalp hair achieved satisfaction in50% of participants. More participants were satisfied with complete eyebrows and no scalp hair (69%) than complete eyebrows and partial scalp hair (51%). Only when both eyebrows and scalp hair were completely regrown did extreme satisfaction levels reach 90.4%. Limitations include the online nature of the survey, lack of control group, and self-reported severity of alopecia areata in participants. These results suggest that eyebrows may be as important as scalp hair for patients assessing theoretical responses to treatment for alopecia areata. Future clinical studies should consider growth of eyebrows as an outcome measure on par with scalp hair growth. more...
- Published
- 2020
- Full Text
- View/download PDF
6. Dermatologic toxicities of targeted antineoplastic agents and immune checkpoint inhibitor therapy in pediatric patients: A systematic review
- Author
-
Lucy Y. Liu, Jenna Strelo, Bernice Y. Kwong, Joyce M.C. Teng, Sheri L. Spunt, and Lisa C. Zaba
- Subjects
Oncology ,medicine.medical_specialty ,Immune checkpoint inhibitors ,medicine.medical_treatment ,Antineoplastic Agents ,Timely diagnosis ,Targeted therapy ,Neoplasms ,Internal medicine ,medicine ,Pediatric oncology ,Humans ,Child ,Adverse effect ,Immune Checkpoint Inhibitors ,Skin ,business.industry ,Cancer ,Hematology ,Immunotherapy ,medicine.disease ,Pediatrics, Perinatology and Child Health ,Quality of Life ,Dose reduction ,business - Abstract
Cutaneous adverse events (cAEs) from targeted antineoplastic agents and immune checkpoint inhibitors are common in children with cancer and may lead to dose reduction or cessation of critical oncologic treatment. Timely diagnosis and proper management of cAEs in pediatric oncology patients is essential to optimize ongoing cancer-directed therapy and improve quality of life. This systematic review of published studies summarizes dermatologic toxicities to targeted anticancer treatments and immune checkpoint inhibitors. more...
- Published
- 2021
- Full Text
- View/download PDF
7. Inhibiting PI3K and MAPK Pathways
- Author
-
Lucy Y. Liu, Michael R. Jeng, and Joyce M. C. Teng
- Published
- 2022
- Full Text
- View/download PDF
8. Ruxolitinib for the treatment of severe alopecia areata
- Author
-
Lucy Y. Liu and Brett A. King
- Subjects
Adult ,Male ,Ruxolitinib ,medicine.medical_specialty ,Adolescent ,Alopecia Areata ,Treatment outcome ,Dermatology ,Severity of Illness Index ,Drug Administration Schedule ,Sampling Studies ,Young Adult ,Piperidines ,Nitriles ,medicine ,Humans ,Pyrroles ,Retrospective Studies ,Dose-Response Relationship, Drug ,business.industry ,Alopecia totalis ,Middle Aged ,Alopecia areata ,medicine.disease ,Pyrimidines ,Treatment Outcome ,Patient Satisfaction ,Alopecia universalis ,Pyrazoles ,Female ,business ,Hair ,medicine.drug - Published
- 2019
- Full Text
- View/download PDF
9. Efficacy of regional nodal ultrasound surveillance for metastatic detection in sentinel- and complete lymph node dissection-eligible melanoma patients
- Author
-
Samvel Gyurdzhyan, Lucy Y. Liu, Susan M. Swetter, and Lisa C. Zaba
- Subjects
Cancer Research ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Melanoma ,Ultrasound ,Sentinel lymph node ,medicine.disease ,Dissection ,medicine.anatomical_structure ,Oncology ,Biopsy ,Cutaneous melanoma ,medicine ,Radiology ,business ,NODAL ,Lymph node - Abstract
e21568 Background: Nodal ultrasound (US) is the preferred method for regional surveillance of clinically node-negative (cN0) primary cutaneous melanoma (CM) when sentinel lymph node biopsy (SLNB) is not performed or unsuccessful, and for pathologically node-positive (pN+) disease without completion lymph node dissection (CLND). Methods: Retrospective review was performed of nodal US surveillance from 2011-2021 in SLNB-eligible cN0 CM patients when SLNB was deferred or technically not feasible ( i.e., from failure of lymphoscintigraphic dye migration) or those with pN+ disease on SLNB, without subsequent CLND. Patients were followed for at least 2 years or until recurrence. The primary endpoints were US detection of regional nodal recurrence and comparison to clinical exam or cross-sectional imaging (PET-CT and/or CT). Results: In total, 67 patients met inclusion criteria and underwent a median of 4 nodal US exams (interquartile range, IQR 3-5) over 2-3 years of follow-up. Thirty-two (47.8%) patients declined or had unsuccessful SLNB, and 35 (52.2%) deferred CLND in favor of nodal US surveillance. Sixteen (23.9%) patients had clinical stage IA/IB (cIA/IB) CM, 15 (22.3%) had clinical stage II (cII) disease, and 36 (53.7%) had pathologic stage III (pIII) disease. Three (4.5%) patients developed satellite/in-transit metastasis, 6 (8.9%) had regional nodal recurrence, 4 (6.0%) had both local and regional recurrence, and 7 (10.4%) developed distant metastasis. Eighteen (26.9%) patients underwent tissue sampling, with 10 positive for melanoma. Nodal recurrence was observed in patients with initial cIB (1), cIIA (1), cIIB (1), cIIC (2), pIIIA (1), and pIIIC (4) disease. Three patients (cIIA, cIIB, and pIIIC due to microsatellites) had abnormal clinical exams with concurrent palpable regional adenopathy and in-transit metastasis. One patient (pIIIC) developed local satellite metastasis followed by palpable regional adenopathy. The most common surveillance method for metastatic detection was US (6/10), followed by clinical exam (3/10) and PET-CT (1/10). All metastatic nodes on US were metabolically active on subsequent PET-CT. One patient in whom PET-CT was the initial method of detection had no confirmatory US. Conclusions: Nodal US for CM requires specific radiologic expertise and is gaining traction as a cost-effective imaging modality in the United States. Our findings support the effectiveness of nodal US surveillance in cN0 or pN+ CM patients in whom SLNB or CLND is not performed.[Table: see text] more...
- Published
- 2021
- Full Text
- View/download PDF
10. Tofacitinib for the treatment of alopecia areata and variants in adolescents
- Author
-
Brett A. King, Lucy Y. Liu, and Brittany G. Craiglow
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Alopecia Areata ,Dermatology ,Disease ,Severity of Illness Index ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Piperidines ,medicine ,Humans ,Pyrroles ,Adverse effect ,Protein Kinase Inhibitors ,Retrospective Studies ,Tofacitinib ,business.industry ,Alopecia ,Alopecia areata ,medicine.disease ,Clinical trial ,Pyrimidines ,Treatment Outcome ,030220 oncology & carcinogenesis ,Review of systems ,Alopecia universalis ,Female ,Janus kinase ,business - Abstract
Background There are no reliably effective therapies for alopecia areata (AA). Objective We sought to evaluate the benefit and adverse effects of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of adolescent patients with AA. Methods We reviewed the records of 13 adolescent patients with AA treated with tofacitinib. Severity of disease was assessed using the Severity of Alopecia Tool (SALT). Adverse events were evaluated by laboratory monitoring, physical examinations, and review of systems. Results Thirteen patients, aged 12 to 17 years, with AA were treated with tofacitinib. Nine patients experienced clinically significant hair regrowth. Median percent change in SALT score was 93% (mean 61%; 1%-100%) at an average of 6.5 months of treatment. Adverse events were mild. Limitations Limitations include the retrospective nature of the data, small sample size, and lack of a control group. Conclusion Tofacitinib is a promising therapy for AA in adolescents. The use of tofacitinib and other Janus kinase inhibitors for the treatment of AA in this age group should be further evaluated in prospective clinical trials. more...
- Published
- 2017
- Full Text
- View/download PDF
11. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Author
-
Brett A. King, Feng Dai, Lucy Y. Liu, and Brittany G. Craiglow
- Subjects
medicine.medical_specialty ,Tofacitinib ,integumentary system ,business.industry ,Alopecia totalis ,Retrospective cohort study ,Dermatology ,Alopecia areata ,medicine.disease ,law.invention ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,030220 oncology & carcinogenesis ,Alopecia universalis ,medicine ,Clinical endpoint ,skin and connective tissue diseases ,Adverse effect ,business - Abstract
Background Alopecia areata (AA) is a common autoimmune disorder. There are no reliably effective therapies for AA. Objective We sought to evaluate the safety and efficacy of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of patients over an extended period of time. Methods This is a retrospective study of patients age 18 years or older with AA with at least 40% scalp hair loss treated with tofacitinib. The primary end point was the percent change in Severity of Alopecia Tool (SALT) score during treatment. Results Ninety patients met inclusion criteria. Of 65 potential responders to therapy, defined as those with alopecia totalis or alopecia universalis with duration of current episode of disease of 10 years or less or alopecia areata, 77% achieved a clinical response, with 58% of patients achieving greater than 50% change in SALT score over 4 to 18 months of treatment. Patients with AA experienced a higher percent change in SALT score than did patients with alopecia totalis or alopecia universalis (81.9% vs 59.0%). Tofacitinib was well tolerated, and there were no serious adverse events. Limitations The retrospective nature of the data, the relatively small number of patients, and lack of a control group are limitations. Conclusion Tofacitinib should be considered for the treatment of severe AA, alopecia totalis, and alopecia universalis; tofacitinib dose response will be better defined by randomized controlled trials. more...
- Published
- 2017
- Full Text
- View/download PDF
12. Neuromonitoring Using Motor and Somatosensory Evoked Potentials in Aortic Surgery
- Author
-
Lucy Y. Liu, Brooke Callahan, John A. Elefteriades, Sven Peterss, Julia Dumfarth, Maryann Tranquilli, and Bulat A. Ziganshin
- Subjects
Pulmonary and Respiratory Medicine ,medicine.diagnostic_test ,business.industry ,030204 cardiovascular system & hematology ,Hematocrit ,Spinal cord ,medicine.disease ,03 medical and health sciences ,Aortic aneurysm ,0302 clinical medicine ,medicine.anatomical_structure ,030228 respiratory system ,Somatosensory evoked potential ,Anesthesia ,medicine ,Paralysis ,Surgery ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Paraplegia ,Stroke ,Spinal cord injury - Abstract
Background Motor evoked potentials (MEP) and somatosensory evoked potentials (SSEP) are established methods of neuromonitoring aimed at preventing paraplegia after descending or thoracoabdominal aortic repair. However, their predictive impact remains controversial. The aim of this study was to evaluate our single-center experience using this monitoring technique. Methods Between 2009 and 2014, 78 patients (mean age 66 ± 12, 53% male) underwent either descending or thoracoabdominal aortic repairs. Of these, 60% had an aortic aneurysm, 30% dissection, and 10% other etiologies. Intraoperatively, MEPs and SSEPs were monitored and, if necessary, clinical parameters (blood pressure, hematocrit, oxygenation) were adjusted in response to neuromonitoring signals. This analysis is focused on the neurological outcome (paraplegia, stroke) after the use of intraoperative neuromonitoring. Results Thirty-day mortality was 10 (12.8%). All patients with continuously stable signals or signals that returned after signal loss developed no spinal cord injury, whereas two out of six of the evaluable patients with signal loss (without return) during the procedure suffered from postoperative paraplegia (one transient and one permanent). Sensitivity and specificity of use of MEP and SSEP were 100% and 94.20% regarding paraplegia, respectively. Conclusions (1) Preservation of signals or return of signals is an excellent prognostic indicator for spinal cord function. (2) Intraoperative modifications in direct response to the signal change may have averted permanent paralysis in the patients with signal loss without neurologic injury. We have found MEP and SSEP neuromonitoring to be instrumental in the prevention of paraplegia. doi: 10.1111/jocs.12739 (J Card Surg 2016;31:383–389) more...
- Published
- 2016
- Full Text
- View/download PDF
13. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- Author
-
Lucy Y. Liu and Brett A. King
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Ruxolitinib ,Adolescent ,Alopecia Areata ,Administration, Topical ,Dermatology ,Autoimmune Diseases ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Piperidines ,medicine ,Humans ,Janus Kinase Inhibitors ,Pyrroles ,Molecular Biology ,Autoimmune disease ,Clinical Trials as Topic ,Tofacitinib ,business.industry ,Alopecia totalis ,Cell Biology ,General Medicine ,Alopecia areata ,medicine.disease ,Clinical trial ,Pyrimidines ,030104 developmental biology ,Alopecia universalis ,Female ,Janus kinase ,business ,Algorithms ,Biotechnology ,medicine.drug - Abstract
Alopecia areata (AA) is an autoimmune disease affecting people of all ages. There is currently no cure for AA, and a highly efficacious therapy for severe AA has been elusive. Recently, scientific advances have identified the Janus kinase pathway as a target for treatment. Both Janus kinase inhibitors approved by the US Food and Drug Administration, tofacitinib and ruxolitinib, have shown promise in open-label clinical trials. This review summarizes the results of long-term use of tofacitinib in severe AA. more...
- Published
- 2018
- Full Text
- View/download PDF
14. Exposure-response (E-R) efficacy and safety (E-S) analyses of tremelimumab as monotherapy or in combination with durvalumab in patients (pts) with unresectable hepatocellular carcinoma (uHCC)
- Author
-
Xuyang Song, Philip He, Robin Kate Kelley, Alejandra Negro, Anis A. Khan, Ghassan K. Abou-Alfa, Michelle F. Green, Rajesh Krishna, Kun Wang, Patricia McCoon, Nathan Standifer, Rajesh Narwal, and Lucy Y. Liu more...
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Durvalumab ,business.industry ,Phases of clinical research ,Priming (immunology) ,medicine.disease ,Regimen ,Internal medicine ,Hepatocellular carcinoma ,medicine ,In patient ,business ,Exposure response ,Tremelimumab ,medicine.drug - Abstract
313 Background: In a phase II study in uHCC (Study 22, NCT02519348), a novel, priming combination regimen of tremelimumab (T; anti-CTLA-4) and durvalumab (D; anti-PD-L1) (T300+D) has shown favorable clinical activity vs each agent as monotherapy or vs another combination (T75+D). The analyses presented here assess the pharmacokinetics (PK) and relationships between tremelimumab exposure, as monotherapy or in combination, and safety, efficacy, and pharmacodynamics (PD) in this study. Methods: Overall, 216 pts were included in these analyses (T, n=65; T300+D, n=72; T75+D, n=79). Safety, antitumor activity, PK, PD, and immunogenicity were analyzed using standard pharmacometrics methods. A previously developed population PK model for T across solid tumors was validated using T monotherapy and combination therapy data from Study 22, including a post-hoc covariate analysis to assess the impact of covariates on individual PK parameters. Population PK and PD models related individual T exposures to safety parameters, PD, and efficacy (overall survival, OS; progression-free survival, PFS; and objective response rate, ORR). The E-R relationships for time-to-event variables OS and PFS were explored by Kaplan-Meier estimates and analyzed by Cox proportional-hazards models (CPHM). Results: For T monotherapy and T+D combinations, no significant E-S relationships were observed for grade 3/4 treatment-related adverse events (TRAEs), grade 3/4 TRAEs of special interest, and AEs leading to treatment discontinuation. Analyses of each quartile of T exposure suggest pts with higher exposure (3rd and 4th quartile) may have longer OS vs lower quartiles. The CPHManalysis showed that after accounting for prognostic factors (baseline albumin and neutrophil-to-lymphocyte ratio), neither AUC nor Cmin appeared to be a significant factor for OS hazard. There was no significant relationship between response and ORR, PFS and any T PK exposure metric in T-treated pts. Saturable relationships (described by Emax) were observed for maximum change from baseline for proliferating T-cell counts as functions of exposure. Conclusions: The observed PK data are generally consistent with predictions based on a historical population PK model, suggesting the PK of T in uHCC pts is consistent with pts with other solid tumors. No significant relationships were observed between E-S and E-R; therefore, PK is not a significant predictor to evaluate for T efficacy or safety. Considering the small sample size limitation, still the saturable relationships observed in proliferating T-cells appear to support a dose of T300. Future studies of pooled data from Study 22 and the larger phase III HIMALAYA study (NCT03298451) will be conducted to further the characterization of E-R relationships and the development of the T300+D regimen. Clinical trial information: NCT02519348. more...
- Published
- 2021
- Full Text
- View/download PDF
15. Peristomal Nodule in a Patient With Ovarian Cancer
- Author
-
Sarika Ramachandran, Lucy Y. Liu, and Sara H. Perkins
- Subjects
0301 basic medicine ,Ovarian Neoplasms ,medicine.medical_specialty ,Skin Neoplasms ,business.industry ,Biopsy ,Nodule (medicine) ,General Medicine ,Adenocarcinoma ,Middle Aged ,medicine.disease ,Dermatology ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Colostomy ,medicine ,Humans ,Female ,medicine.symptom ,business ,Ovarian cancer ,Sister Mary Joseph's Nodule - Published
- 2018
16. Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata
- Author
-
Lucy Y. Liu and Brett A. King
- Subjects
Adult ,Male ,medicine.medical_specialty ,Alopecia Areata ,Administration, Topical ,MEDLINE ,Dermatology ,Tofacitinib therapy ,Risk Assessment ,Cohort Studies ,Young Adult ,Piperidines ,Humans ,Medicine ,Pyrroles ,Young adult ,Retrospective Studies ,Eyelashes ,business.industry ,Follow up studies ,Retrospective cohort study ,Middle Aged ,Alopecia areata ,medicine.disease ,Pyrimidines ,Treatment Outcome ,Female ,Eyebrows ,business ,Risk assessment ,Follow-Up Studies ,Cohort study - Published
- 2019
- Full Text
- View/download PDF
17. Routine Genetic Testing for Thoracic Aortic Aneurysm and Dissection in a Clinical Setting
- Author
-
Maryann Tranquilli, Daniel J. Dykas, Bulat A. Ziganshin, Lokman H. Tanriverdi, Allison E. Bailey, Lucy Y. Liu, Celinez Coons, Paris Charilaou, Allen E. Bale, and John A. Elefteriades
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Pathology ,Adolescent ,Thoracic aortic aneurysm ,Young Adult ,Aortic aneurysm ,Internal medicine ,medicine ,Humans ,FLNA ,Genetic Testing ,Exome sequencing ,Aged ,Retrospective Studies ,Genetic testing ,Aged, 80 and over ,Aortic Aneurysm, Thoracic ,medicine.diagnostic_test ,business.industry ,MYLK ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Pedigree ,Aortic Dissection ,Dissection ,Female ,Surgery ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies ,Genome-Wide Association Study - Abstract
Background Hereditary factors play an important etiologic role in thoracic aortic aneurysm and dissection (TAAD), with a number of genes proven to predispose to this condition. We initiated a clinical program for routine genetic testing of individuals for TAAD by whole exome sequencing (WES). Here we present our initial results. Methods The WES was performed in 102 patients (mean age 56.8 years; range 13 to 83; 70 males [68.6%]) with TAAD. The following 21-gene panel was tested by WES: ACTA2, ADAMTS10, COL1A1, COL1A2, COL3A1, COL5A1, COL5A2, ELN, FBLN4, FLNA, FBN1, FBN2, MYH11, MYLK, NOTCH1, PRKG1, SLC2A10, SMAD3, TGFB2, TGFBR1, TGFBR2. Results Seventy-four patients (72.5%) had no medically important genetic alterations. Four patients (3.9%) had a deleterious mutation identified in the FBN1, COL5A1, MYLK, and FLNA genes. Twenty-two (21.6%) previously unreported suspicious variants of unknown significance were identified in 1 or more of the following genes: FBN1 (n = 5); MYH11 (n = 4); ACTA2 (n = 2); COL1A1 (n = 2); TGFBR1 (n = 2); COL3A1 (n = 1); COL5A1 (n = 1); COL5A2 (n = 1); FLNA (n = 1); NOTCH1 (n = 1); PRKG1 (n = 1); and TGFBR3 (n = 1). Identified mutations had implications for clinical management. Conclusions Routine genetic screening of patients with TAAD provides information that enables genetically personalized care and permits identification of novel mutations responsible for aortic pathology. Analysis of large data sets of variants of unknown significance that include associated clinical features will help define the mutational spectrum of known genes underlying this phenotype and potential identify new candidate loci. more...
- Published
- 2015
- Full Text
- View/download PDF
18. Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families
- Author
-
Lucy Y. Liu, Brett A. King, and Brittany G. Craiglow
- Subjects
Gerontology ,Adult ,Male ,Alopecia Areata ,MEDLINE ,Self-concept ,Dermatology ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Quality of life (healthcare) ,Surveys and Questionnaires ,medicine ,Humans ,Family ,Affective Symptoms ,Social isolation ,Child ,Health related quality of life ,business.industry ,Age Factors ,Dermatology Life Quality Index ,Alopecia areata ,Middle Aged ,medicine.disease ,Self Concept ,Patient Health Questionnaire ,Social Isolation ,030220 oncology & carcinogenesis ,Quality of Life ,Female ,medicine.symptom ,business - Published
- 2017
19. Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life
- Author
-
Lucy Y. Liu, Brittany G. Craiglow, and Brett A. King
- Subjects
Moderate to severe ,Adult ,Male ,medicine.medical_specialty ,Alopecia Areata ,Emotions ,Dermatology ,Severity of Illness Index ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Piperidines ,Surveys and Questionnaires ,Medicine ,Humans ,Pyrroles ,Protein Kinase Inhibitors ,Health related quality of life ,business.industry ,Alopecia areata ,Middle Aged ,medicine.disease ,Pyrimidines ,030220 oncology & carcinogenesis ,Quality of Life ,Female ,business - Published
- 2017
20. Repigmentation in vitiligo using the janus kinase inhibitor, tofacitinib, may require concomitant light exposure
- Author
-
Brett A. King, Lucy Y. Liu, Maggi Ahmed Refat, James P. Strassner, and John E. Harris
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Ruxolitinib ,medicine.medical_treatment ,Vitiligo ,Autoimmunity ,Skin Pigmentation ,Dermatology ,Chemokine CXCL9 ,Severity of Illness Index ,Article ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Depigmentation ,Piperidines ,medicine ,Humans ,Pyrroles ,skin and connective tissue diseases ,Protein Kinase Inhibitors ,Janus kinase inhibitor ,Aged ,Retrospective Studies ,Autoimmune disease ,Tofacitinib ,business.industry ,Janus Kinase 3 ,Immunosuppression ,Janus Kinase 1 ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Chemokine CXCL10 ,030104 developmental biology ,Pyrimidines ,Female ,Ultraviolet Therapy ,medicine.symptom ,business ,Janus kinase ,medicine.drug - Abstract
Background Vitiligo is an autoimmune disease in which cutaneous depigmentation occurs. Existing therapies are often inadequate. Prior reports have shown benefit of the Janus kinase (JAK) inhibitors. Objective To evaluate the efficacy of the JAK 1/3 inhibitor tofacitinib in the treatment of vitiligo. Method This is a retrospective case series of 10 consecutive patients with vitiligo treated with tofacitinib. Severity of disease was assessed by body surface area of depigmentation. Results Ten consecutive patients were treated with tofacitinib. Five patients achieved some repigmentation at sites of either sunlight exposure or low-dose narrowband ultraviolet B phototherapy. Suction blister sampling revealed that the autoimmune response was inhibited during treatment in both responding and nonresponding lesions, suggesting that light rather than immunosuppression was primarily required for melanocyte regeneration. Limitations Limitations include the small size of the study population, retrospective nature of the study, and lack of a control group. Conclusion Treatment of vitiligo with JAK inhibitors appears to require light exposure. In contrast to treatment with phototherapy alone, repigmentation during treatment with JAK inhibitors may require only low-level light. Maintenance of repigmentation may be achieved with JAK inhibitor monotherapy. These results support a model wherein JAK inhibitors suppress T cell mediators of vitiligo and light exposure is necessary for stimulation of melanocyte regeneration. more...
- Published
- 2017
21. Lack of efficacy of apremilast in 9 patients with severe alopecia areata
- Author
-
Brett A. King and Lucy Y. Liu
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Alopecia Areata ,Dermatology ,Risk Assessment ,Severity of Illness Index ,Treatment failure ,Drug Administration Schedule ,Sampling Studies ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Sex Factors ,Sex factors ,Internal medicine ,Severity of illness ,Lack of efficacy ,Medicine ,Humans ,Treatment Failure ,Aged ,Retrospective Studies ,Dose-Response Relationship, Drug ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Age Factors ,Alopecia areata ,Middle Aged ,medicine.disease ,Thalidomide ,Endocrinology ,030220 oncology & carcinogenesis ,Alopecia universalis ,Female ,Apremilast ,business ,Needs Assessment ,medicine.drug - Published
- 2017
22. IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans
- Author
-
Carlos Gustavo Wambier, Lucy Y. Liu, Sydney Crotts, Renato Soriani Paschoal, Sa Rang Kim, Luana dos Santos Ortolan, Brett A. King, Ali Jabbari, and Brittany G. Craiglow
- Subjects
Male ,0301 basic medicine ,Immunology ,Disease ,Article ,Neutralization ,Mice ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Ustekinumab ,Interleukin 23 ,Animals ,Humans ,Immunology and Allergy ,Medicine ,skin and connective tissue diseases ,integumentary system ,biology ,Interleukin-12 Subunit p40 ,business.industry ,Alopecia ,Alopecia areata ,medicine.disease ,Antibodies, Neutralizing ,030104 developmental biology ,Murine model ,Interleukin-23 Subunit p19 ,Interleukin 12 ,biology.protein ,Female ,Antibody ,business ,medicine.drug - Abstract
Ustekinumab is currently being explored for the treatment of alopecia areata. Here, our work in a murine model and in human patients indicates that neutralization of the IL-12 and IL-23 pathways does not ameliorate disease. more...
- Published
- 2019
- Full Text
- View/download PDF
23. Pathologic leadpoint is uncommon in ileo-colic intussusception regardless of age
- Author
-
Michael G. Caty, Jill C. Rubinstein, Emily R. Christison-Lagay, and Lucy Y. Liu
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Subgroup analysis ,Age groups ,Intussusception (medical disorder) ,Humans ,Medicine ,Child ,Anatomic Location ,Retrospective Studies ,Barium enema ,Retrospective review ,Ileal Diseases ,business.industry ,Incidence (epidemiology) ,Age Factors ,Infant ,General Medicine ,medicine.disease ,Bowel intussusception ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Female ,Surgery ,business ,Intussusception - Abstract
Purpose Historically, the rate of pathologic leadpoints in older children with intussusception is quoted as 20%–25%. Our anecdotal experience suggested a lower rate. We therefore compiled a case series to examine the actual incidence of pathologic leadpoint, and treatment success, by age. Methods A retrospective review was performed of all patients admitted with intussusception between 1998 and 2012 and tested for differences in anatomic location, presence of pathologic leadpoint, and need for operative intervention, on the basis of age. Results In total, 154 cases of intussusception were diagnosed in 141 patients (136 ileo-colic), 38 of which were in children older than 3 (29 ileo-colic). Considering all anatomic locations, older children were more likely to have a pathologic leadpoint (p-value 0.01); however subgroup analysis of ileo-colic intussusception demonstrated no difference (p-value 0.38). Additionally, there was no difference in the success of pneumatic or barium enema reduction on the basis of age (p-value 0.56). Conclusion Despite historical reports of increased pathologic leadpoints in ileo-colic intussusception in older children, in this series the majority were idiopathic. Non-operative management was successful approximately 75% of the time, irrespective of age. In older age groups, there was an increased frequency of pathologic leadpoints in small bowel-small bowel intussusception. more...
- Published
- 2015
- Full Text
- View/download PDF
24. Analysis of fast boundary-integral approximations for modeling electrostatic contributions of molecular binding
- Author
-
Amelia B. Kreienkamp, Matthew G. Knepley, Mala L. Radhakrishnan, Lucy Y. Liu, Jaydeep P. Bardhan, and Mona S. Minkara
- Subjects
Computer science ,Implicit solvation ,Biophysics ,Boundary (topology) ,Component analysis ,boundary-element methods ,Article ,92C05 ,Limit (mathematics) ,Statistical physics ,implicitsolvent models ,lcsh:QH301-705.5 ,Molecular Biology ,Mathematical Physics ,Eigenvalues and eigenvectors ,BIBEE ,molecular electrostatics ,lcsh:Mathematics ,Applied Mathematics ,Operator (physics) ,65N38 ,lcsh:QA1-939 ,continuum solvation ,Data science ,Computational Mathematics ,Dipole ,lcsh:Biology (General) ,92C40 ,Quadrupole ,65N80 ,Interpolation - Abstract
We analyze and suggest improvements to a recently developed approximate continuum-electrostatic model for proteins. The model, called BIBEE/I (boundary-integral based electrostatics estimation with interpolation), was able to estimate electrostatic solvation free energies to within a mean unsigned error of 4% on a test set of more than 600 proteins¶a significant improvement over previous BIBEE models. In this work, we tested the BIBEE/I model for its capability to predict residue-by-residue interactions in protein–protein binding, using the widely studied model system of trypsin and bovine pancreatic trypsin inhibitor (BPTI). Finding that the BIBEE/I model performs surprisingly less well in this task than simpler BIBEE models, we seek to explain this behavior in terms of the models’ differing spectral approximations of the exact boundary-integral operator. Calculations of analytically solvable systems (spheres and tri-axial ellipsoids) suggest two possibilities for improvement. The first is a modified BIBEE/I approach that captures the asymptotic eigenvalue limit correctly, and the second involves the dipole and quadrupole modes for ellipsoidal approximations of protein geometries. Our analysis suggests that fast, rigorous approximate models derived from reduced-basis approximation of boundaryintegral equations might reach unprecedented accuracy, if the dipole and quadrupole modes can be captured quickly for general shapes. more...
- Published
- 2013
- Full Text
- View/download PDF
25. Neonatal Subgaleal Hematoma from Trauma During Vaginal Delivery without Instrument Use
- Author
-
Richard J. Antaya and Lucy Y. Liu
- Subjects
Male ,medicine.medical_specialty ,Birth trauma ,Subgaleal hematoma ,Gestational Age ,Dermatology ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Risk Factors ,Birth Injuries ,medicine ,Humans ,Caput succedaneum ,Hematoma ,030219 obstetrics & reproductive medicine ,Scalp ,Vaginal delivery ,business.industry ,Ultrasound ,Infant, Newborn ,Gestational age ,medicine.disease ,Delivery, Obstetric ,Surgery ,Pediatrics, Perinatology and Child Health ,Cephalohematoma ,Female ,business ,030217 neurology & neurosurgery - Abstract
Neonatal subgaleal hematomas (SGHs) are rare but potentially life-threatening complications of vacuum extraction deliveries. We report a rare case of four enlarging SGHs in an 11-day-old boy born without use of instruments during delivery. It is likely that trauma from the provider's fingers caused these SGHs during a normal vaginal delivery. Ultrasound findings confirmed the diagnosis of SGH, distinct from other birth trauma such as cephalohematoma or caput succedaneum. more...
- Published
- 2016
26. Rapid repigmentation of vitiligo with tofacitinib plus low-dose narrowband ultraviolet B (nbUVB), even following depigmentation with monobenzyl ether of hydroquinone
- Author
-
Sa Kim, Brett A. King, Henry Heaton, and Lucy Y. Liu
- Subjects
medicine.medical_specialty ,Tofacitinib ,Hydroquinone ,business.industry ,Low dose ,Ultraviolet b ,Ether ,Dermatology ,Vitiligo ,medicine.disease ,chemistry.chemical_compound ,Depigmentation ,chemistry ,medicine ,medicine.symptom ,business - Published
- 2018
- Full Text
- View/download PDF
27. High sintering resistance of a novel thermal barrier coating
- Author
-
Peter Howard, Ravi Shankar, and Lucy Y. Liu
- Subjects
Materials science ,Metallurgy ,Sintering ,Surfaces and Interfaces ,General Chemistry ,Chemical vapor deposition ,Plasma ,Condensed Matter Physics ,Microstructure ,Electron beam physical vapor deposition ,Surfaces, Coatings and Films ,Thermal barrier coating ,Powder metallurgy ,Physical vapor deposition ,Materials Chemistry - Abstract
Sintering resistance of a novel thermal barrier coating NdxZr1 − xOy with Z dissolved in, where 0
- Published
- 2010
- Full Text
- View/download PDF
28. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy
- Author
-
Sa Rang Kim, Henry Heaton, Brett A. King, and Lucy Y. Liu
- Subjects
medicine.medical_specialty ,Tofacitinib ,business.industry ,Low dose ,Dermatology ,Vitiligo ,medicine.disease ,Ultraviolet therapy ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Ultraviolet B radiation ,Narrowband ,030220 oncology & carcinogenesis ,medicine ,Combined Modality Therapy ,business - Published
- 2018
- Full Text
- View/download PDF
29. In reply
- Author
-
Lucy Y, Liu and Brett A, King
- Subjects
Dermatology - Published
- 2018
- Full Text
- View/download PDF
30. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
- Author
-
Brittany G. Craiglow, Lucy Y. Liu, and Brett A. King
- Subjects
Adult ,Male ,medicine.medical_specialty ,Alopecia Areata ,Pilot Projects ,Dermatology ,Ointments ,Young Adult ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Piperidines ,Humans ,Medicine ,Pyrroles ,Protein Kinase Inhibitors ,Janus kinase inhibitor ,Tofacitinib ,business.industry ,Middle Aged ,Alopecia areata ,medicine.disease ,Pyrimidines ,030220 oncology & carcinogenesis ,Female ,business ,Hair - Published
- 2018
- Full Text
- View/download PDF
31. Functional profiling of the Saccharomyces cerevisiae genome
- Author
-
Bart Scherens, Ning Lan, Steeve Veronneau, Anna Astromoff, Matt Curtiss, Ronald W. Davis, Jeffrey N. Strathern, Marleen Voet, Johannes H. Hegemann, Ankuta Lucau-Danila, Petra Ross-Macdonald, Adam M. Deutschbauer, Françoise Foury, Greg Schimmack, Daniel D. Shoemaker, Karen Davis, Rhonda Bangham, Darlene LaBonte, Christopher J. Roberts, Zelek S. Herman, Patrick Flaherty, Stefano Campanaro, Patrice Menard, Michael Snyder, Teresa R. Ward, Adam P. Arkin, Howard Bussey, Linda Riles, Yonghong Yang, Grace Yen, Guri Giaever, K. D. Entian, Kexin Yu, Elaine M. Youngman, Sharon Sookhai-Mahadeo, Jef D. Boeke, Reginald Storms, Daniel F. Jaramillo, Giorgio Valle, José L. Revuelta, Sally Dow, Mark Johnston, Matthias Rose, Mohamed El Bakkoury, Deanna Gotte, Hong Liao, Elizabeth A. Winzeler, Brenda Shafer, Marc Lussier, Chuanyun Luo, Siew Loon Ooi, Peter Philippsen, Angela M. Chu, Guido Volckaert, Rong Mao, Peter Kötter, Keith Anderson, Ching Yun Wang, Julie Wilhelmy, Ulrich Güldener, Li Ni, Lucy Y. Liu, Mark Gerstein, David C. Lamb, Steven L. Kelly, Carla Connelly, Diane E. Kelly, Svenja Hempel, Rocío Benito, David J. Garfinkel, Bruno André, Hong Liang, and Sophie Brachat more...
- Subjects
Nystatin ,Saccharomyces cerevisiae Proteins ,Proteome ,Genes, Fungal ,Saccharomyces cerevisiae ,Genomics ,Saccharomyces ,Genome ,Open Reading Frames ,Cluster Analysis ,Sorbitol ,Selection, Genetic ,Gene ,Cell Size ,Genetics ,Multidisciplinary ,biology ,Gene Expression Profiling ,Osmolar Concentration ,Galactose ,Hydrogen-Ion Concentration ,biology.organism_classification ,Synthetic genetic array ,Culture Media ,Gene expression profiling ,Phenotype ,Genome, Fungal ,Functional genomics ,Gene Deletion - Abstract
Determining the effect of gene deletion is a fundamental approach to understanding gene function. Conventional genetic screens exhibit biases, and genes contributing to a phenotype are often missed. We systematically constructed a nearly complete collection of gene-deletion mutants (96% of annotated open reading frames, or ORFs) of the yeast Saccharomyces cerevisiae. DNA sequences dubbed 'molecular bar codes' uniquely identify each strain, enabling their growth to be analysed in parallel and the fitness contribution of each gene to be quantitatively assessed by hybridization to high-density oligonucleotide arrays. We show that previously known and new genes are necessary for optimal growth under six well-studied conditions: high salt, sorbitol, galactose, pH 8, minimal medium and nystatin treatment. Less than 7% of genes that exhibit a significant increase in messenger RNA expression are also required for optimal growth in four of the tested conditions. Our results validate the yeast gene-deletion collection as a valuable resource for functional genomics. more...
- Published
- 2002
- Full Text
- View/download PDF
32. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review
- Author
-
Brett A. King, Brittany G. Craiglow, and Lucy Y. Liu
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Alopecia Areata ,SF-36 ,Dermatology ,Risk Assessment ,Severity of Illness Index ,Young Adult ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Sex Factors ,0302 clinical medicine ,Quality of life ,Sickness Impact Profile ,Psoriasis ,Adaptation, Psychological ,medicine ,Humans ,integumentary system ,business.industry ,Alopecia totalis ,Age Factors ,Dermatology Life Quality Index ,Atopic dermatitis ,Middle Aged ,Alopecia areata ,medicine.disease ,humanities ,Case-Control Studies ,030220 oncology & carcinogenesis ,Alopecia universalis ,Quality of Life ,Female ,business - Abstract
Alopecia areata (AA) is a common skin disease that is frequently emotionally devastating. Several studies have examined the effect of AA on health-related quality of life (HRQoL). We performed a systematic review of all published studies of HRQoL in patients with AA. Eleven studies met inclusion criteria, incorporating data from 1986 patients. Patients with AA consistently demonstrate poor HRQoL scores, with greater extent of scalp involvement associated with lower HRQoL. HRQoL experienced by patients with AA is similar to that seen in patients with other chronic skin diseases including atopic dermatitis and psoriasis. more...
- Published
- 2016
- Full Text
- View/download PDF
33. A first-in-human phase I study of CZ48, a lactone ring protected oral camptothecin, in patients with advanced solid tumors
- Author
-
Montaser Shaheen, Douglas R. Coil, Constantine S.A. Markides, Steven D. Weitman, Lucy Y. Liu, Devalingam Mahalingam, Zhisong Cao, Beppino C. Giovanella, Claire F. Verschraegen, and John Sarantopoulos
- Subjects
chemistry.chemical_classification ,Cancer Research ,Stereochemistry ,business.industry ,First in human ,Prodrug ,Pharmacology ,Ring (chemistry) ,Phase i study ,Oncology ,chemistry ,medicine ,In patient ,business ,Camptothecin ,Lactone ,medicine.drug - Abstract
2578 Background: CZ48, the 20-O-propionate ester of camptothecin (CPT), is a prodrug of CPT first described by Cao et al. in 1998. The side-chain is enzymatically cleaved in tissues. This gives rise to CPT, a potent inhibitor of topoisomerase I. Methods: An open-label, single-arm, dose-escalation Phase I study was performed to determine the maximum tolerated dose (MTD) of CZ48 in patients with advanced solid tumors. Initial dosing started qd po 80mg/m2, advancing to 2560mg/m2 for 21 consecutive days, followed by 7 days rest. Dosing was restarted in cohorts of 3 patients tid po at 18mg/m2 and escalated to 1g/m2on a 5 days on, 2 days off schedule for 28 days. Patients were prescreened by measuring CPT levels in plasma following a single pilot dose of CZ48. Dose was doubled until occurrence of at least Grade 2 adverse event, at which time 3+3 patient cohorts with a dose escalation of 33%-100% were implemented. DLT in 2/6 patients defined the MTD as the preceding DLT dose. PK parameters were measured prior to dosing, days 1-5, and day 28 of Cycle 1. Results: Poor absorption led to initial qd dosing reaching 2560mg/m2 with no signs of DLT. Subsequent tid dosing showed improved plasma levels and arrival at DLT. 34 patients were treated across 8 dose levels from 18 to 1000 mg/m2. The most frequent study-related adverse effects were cystitis, vomiting, diarrhea and fatigue. Grade IV toxicities observed were febrile neutropenia, anemia, and thrombocytopenia. Preliminary PK data in the qd dosing showed poor correlation between dose and Cmax or AUC, while PK in tid patients showed slightly improved correlation between dose and both CZ48 AUC (Pearson's correlation coefficient ϱ=0.476, pmax(ϱ =0.51, p2 and 576 mg/m2. Overall toxicity is relatively mild, with DLT being cystitis and myelosuppression. Even with tid dosing, PK values correlate poorly to dose. A new formulation with 3-5 fold higher preclinical absorption values is being considered for introduction into the trial. Clinical trial information: NCT00947739. more...
- Published
- 2013
- Full Text
- View/download PDF
34. Blockage of Biliary Stents - A Correlative Study
- Author
-
Robert Wilson, Chihya Hung, Joseph Leung, Lucy Y. Liu, and Chih Sheng Hung
- Subjects
business.industry ,Bile duct ,medicine.medical_treatment ,Bile duct strictures ,Significant difference ,Gastroenterology ,Lumen (anatomy) ,Stent ,equipment and supplies ,medicine.disease ,surgical procedures, operative ,medicine.anatomical_structure ,Medicine ,Biliary stent ,Radiology, Nuclear Medicine and imaging ,Biliary sludge ,business ,Nuclear medicine ,Saline - Abstract
Blockage of Biliary Stents A Correlative Study Joseph W. Leung, Chih Sheng Hung, Lucy Y. Liu, Chihya Hung, Robert Wilson Background: Biliary sludge is a major cause of stent blockage. Stents placed for benign bile duct strictures require regular exchange (GIE 2001;54:154-61, GIE 2001;54:162-8) to avoid blockage and cholangitis. A retrospective study noted that patients with post liver transplant (OLT) stricture required more frequent stent exchange (GIE 2005;61:AB217). Aim: (1) We analyzed blocked and unblocked stents retrieved from patients to study the correlation between drainage function (% blockage of lumen), sludge deposition (seen on x-ray), sludge weight/cm stent and demographics (age, gender, clinical diagnoses, stent length and duration of stenting). (2) Subgroup analysis was conducted for patients with post-OLT stricture and non-OLT strictures. Method: 106 (10 Fr) stents were removed from 40 patients (M:F Z 22:18) from 11/2002 to 4/2005. X-ray of stents were taken and compared with control, presence of sludge was graded from 0 to CCC. Flow (ml/min) of sterile saline through the stent in the first minute at a constant pressure head of 10 cm was measured and used as a surrogate for drainage function. The % blockage of lumen was read off a flow chart constructed with restricters of different internal diameters. Pearson correlation coefficient (pc), chi-square test and t-test were used to compare the data, (p ! 0.05 is significant). Results: The % blockage of stent lumen and thus reduction in drainage were positively related to the duration of stenting (days) (pc Z 0.457, p ! 0.001), sludge seen on x-ray (pc Z 0.301, p Z 0.002), sludge weight/cm stent (pc Z 0.557, p! 0.001), age (pc Z 0.233, p Z 0.016), and negatively related to stent length (pcZ 0.305, p Z 0.001) but not related to gender (pcZ 0.06, p Z 0.542). Subgroup analyses for post-OLT (12 patients, 36 stents) and non-OLT strictures (28 patients, 70 stents), revealed no significant difference in gender (chi-square test, p Z 0.096), % blockage (t-test, p Z 0.435), duration of stenting (t-test, p Z 0.722), and sludge seen on x-ray (t-test, p Z 0.452) between the two groups. However, non-OLT had higher sludge weight/cm stent than OLT (t-test, p Z 0.002). Mean age of post-OLT patients was younger (ttest, p Z 0.001), and stents length were longer (t-test, p ! 0.001). An obvious reduction in drainage suggesting onset of stent blockage was seen after day 30 and day 50 respectively. Conclusion: Stent blockage due to sludge accumulation is related to duration of stent in-situ. Although recurrent jaundice in post-OLT patients with bile duct stricture treated with stents may be secondary to other liver problems, a repeat ERCP is necessary to rule out early stent malfunction as a cause of recurrent jaundice. more...
- Published
- 2006
- Full Text
- View/download PDF
35. Bacteriology of Blocked and Unblocked Biliary Stents - Impact On Stent Drainage Function
- Author
-
Joseph Leung, Robert Wilson, Chih Sheng Hung, Chihya Hung, and Lucy Y. Liu
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Gastroenterology ,medicine ,Bacteriology ,Biliary stent ,Stent ,Radiology, Nuclear Medicine and imaging ,Radiology ,Drainage ,business ,Surgery - Published
- 2006
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.